Science

May 12, 2025, 09:12

Myeloma Paper of the Day, May 12th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Duke experience of belantamb mafodotin shows ORR of 67%, median PFS 9.5 months, median OS NR at 3-years, cycle delay in 28 (93%) with 85% due to ocular AEs (2% grade ≥3), treatment discontinuation from ocular tox in 4 (13%).”

Title: Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis

Authors: Mihir N. Patel, Susan C. Locke, Caroline Falvey, Jesse D. Troy, Kris W. Herring, Amanda Bolgioni-Smith, Cherie Elcock, Laura Iadeluca, Cristiana Costa Chase, Cristina Gasparetto, Mark S. Newman, Thomas W. LeBlanc

Read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.

More posts featuring Robert Orlowski.

Amanda Bolgioni-Smith belantamb mafodotin cancer Caroline Falvey Cherie Elcock Cristiana Costa Chase Cristina Gasparetto Jesse D. Troy Kris W. Herring Laura Iadeluca Mark S. Newman Mihir N. Patel multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski RRMM Susan C. Locke Thomas W. LeBlanc

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared